{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05123040",
            "orgStudyIdInfo": {
                "id": "2020LS098"
            },
            "secondaryIdInfos": [
                {
                    "id": "MT2020-28",
                    "type": "OTHER",
                    "domain": "Masonic Cancer Center"
                }
            ],
            "organization": {
                "fullName": "Masonic Cancer Center, University of Minnesota",
                "class": "OTHER"
            },
            "briefTitle": "Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids",
            "officialTitle": "Ruxolitinib, Human Chorionic Gonadotropin (uhCG/EGF), and Dose De-escalated Corticosteroids for Treatment of Minnesota High-Risk Acute GVHD (aGVHD): A Phase I/II Study",
            "therapeuticArea": [
                "Other"
            ],
            "study": "ruxolitinib-human-chorionic-gonadotropin-uhcg-egf-and-dose-de-escalated-corticosteroids"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-06-05",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-09",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-09",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-11-03",
            "studyFirstSubmitQcDate": "2021-11-04",
            "studyFirstPostDateStruct": {
                "date": "2021-11-17",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-17",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-20",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Masonic Cancer Center, University of Minnesota",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This multi-center center phase I/II study to establish the lowest possible recommended phase 2 dose (RP2D) of corticosteroids in conjunction with ruxolitinib and uhCG/EGF (a novel combination) for high-risk aGVHD.\n\nThis is a single arm study designed to determine the lowest dose of corticosteroids required (toxicity endpoint) without impairing GVHD complete response or partial response (CR/PR) at day 28 when given in conjunction with uhCG/EGF and ruxolitinib.\n\nAfter completion of the corticosteroid dose finding, the final dose will be carried forward into a two-stage phase II extension trial to confirm safety and make a preliminary determination of efficacy of this novel drug combination for high-risk aGVHD."
        },
        "conditionsModule": {
            "conditions": [
                "Acute-graft-versus-host Disease"
            ],
            "keywords": [
                "aGVHD"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 55,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Ruxolitinib;hCG (Pregnyl\u00ae) ;Corticosteroids",
                    "type": "EXPERIMENTAL",
                    "description": "* Ruxolitinib 10 mg by mouth twice daily (with dose adjustments as indicated) through day 56, followed by taper\n* hCG (Pregnyl\u00ae) 2,000 units/m2 SQ every other day x 3 doses, followed by twice weekly x 14 doses (total 17 doses through day 56)\n* Corticosteroids (Prednisone, or IV methylprednisolone equivalent)\n\n  * Dose level 1 (starting dose) = 1 mg/kg\n  * Dose level 2 = 0.5 mg/kg\n  * Dose level 3 = 0.25 mg/kg\n  * Dose level 4 = 0.1 mg/kg\n  * Dose level 5 = 0 mg/kg",
                    "interventionNames": [
                        "Drug: Ruxolitinib 10 MG Oral Tablet",
                        "Drug: hCG",
                        "Drug: Corticosteroids"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Ruxolitinib 10 MG Oral Tablet",
                    "description": "By mouth twice daily through day 56, then tapered",
                    "armGroupLabels": [
                        "Ruxolitinib;hCG (Pregnyl\u00ae) ;Corticosteroids"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "hCG",
                    "description": "2,000 units/m2 SQ every other day x 3 doses, followed by twice weekly x 14 doses",
                    "armGroupLabels": [
                        "Ruxolitinib;hCG (Pregnyl\u00ae) ;Corticosteroids"
                    ],
                    "otherNames": [
                        "Pregnyl"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Corticosteroids",
                    "description": "Dose level 1 (starting dose) = 1 mg/kg\n\n* Dose level 2 = 0.5 mg/kg\n* Dose level 3 = 0.25 mg/kg\n* Dose level 4 = 0.1 mg/kg\n* Dose level 5 = 0 mg/kg\n\n  \u2022 If dose level 1 is determined to be below the Recommended Phase 2 Dose (RP2D), the dose will be escalated:\n* Dose level -1 = 1.5 mg/kg\n* Dose level -2 = 2 mg/kg",
                    "armGroupLabels": [
                        "Ruxolitinib;hCG (Pregnyl\u00ae) ;Corticosteroids"
                    ],
                    "otherNames": [
                        "Prednisone",
                        "IV methylprednisolone"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Recommend the lowest possible dose for Phase II of corticosteroids when given in combination with ruxolitinib and uhCG/EGF in pediatric based on DLT frequency",
                    "description": "Plan report patients proportions and their 95% confidence intervals of paitents who experience dose limiting toxicity. Determine best dose based on DLT criteria by CTCAE v5.0\n\n* Thrombosis requiring anticoagulation\n* Ascites (grade 3-5)\n* Ovarian hyperstimulation syndrome",
                    "timeFrame": "28 days after therapy"
                },
                {
                    "measure": "Best response of treatment in adult and children",
                    "description": "proportions of complete, partial, mixed, and no response among surviving patients at days 28 after initiation of protocol therapy in pediatric and adult patients with Minnesota high-risk aGVHD",
                    "timeFrame": "28 days after therapy"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Number of participants with treatment-related adverse events as assessed by CTCAE v5.0",
                    "description": "Report any type of adverse event caused by a drug cause by dose of steroids in combination of ruxolitinib and uhCG/EGF.\n\nDue to the complex medical condition of the GVHD patient, monitoring for adverse events will focus on the following events beginning with the date consent is signed and continuing for 30 days after the subject has completed or discontinued from the study or has taken last dose of the study drug.\n\n* Rehospitalization\n* Death\n* Hematologic (grade 3-5 cytopenia)\n* Infections (grade 3-5)\n* Hyperglycemia (grade 3-5)\n* Steroid myopathy (grade 3-5)",
                    "timeFrame": "30 days after treatment"
                },
                {
                    "measure": "Incidence of acute GVHD flare after CR/PR requiring increase of steroids or other systemic treatment",
                    "description": "Find proportion of incidence of acute GVHD",
                    "timeFrame": "28 days after treatment"
                },
                {
                    "measure": "Incidence of acute GVHD flare after CR/PR requiring increase of steroids or other systemic treatment",
                    "description": "Find proportion of incidence of acute GVHD",
                    "timeFrame": "56 days after treatment"
                },
                {
                    "measure": "Compare the rate of treatment failure for acute GVHD after initiation of protocol therapy to historical controls",
                    "description": "Compare count of treatment failure to other number of failures in other historical protocols",
                    "timeFrame": "28 days after treatment"
                },
                {
                    "measure": "Compare the rate of treatment failure for acute GVHD after initiation of protocol therapy to historical controls",
                    "description": "Compare count of treatment failure to other number of failures in other historical protocols",
                    "timeFrame": "56 days after treatment"
                },
                {
                    "measure": "To assess patient quality of life on study",
                    "description": "Have participants take an overall survival survey",
                    "timeFrame": "6 month after treatment"
                },
                {
                    "measure": "Determine 1-year overall survival",
                    "description": "Provide proportions and their 95% confidence intervals of patients still alive at one year post-treatment",
                    "timeFrame": "1 year post treatment"
                },
                {
                    "measure": "Non-relapse mortality (death without recurrent or progressive disease after allo-HSCT)",
                    "description": "Provide proportions and their 95% confidence intervals of patients who expedience a non-relapse mortality.",
                    "timeFrame": "1 year post treatment"
                },
                {
                    "measure": "Collect blood samples and rectosigmoid biopsies for future correlative studies",
                    "description": "Give a count of the number of patients who had blood and rectosigmoid biopsies",
                    "timeFrame": "1 year after treament"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nHCT recipients over 12 years of age within the first 7 days of initial treatment of high-risk aGVHD, defined as:\n\n* Newly diagnosed Minnesota high-risk aGVHD -OR-\n* Newly diagnosed Minnesota standard risk aGVHD with plasma amphiregulin \u2265 33 pg/ml tested at the UMN Cytokine Reference Lab. For amphiregulin lab ordering information, see Fairview Lab Guide: http://labguide.fairview.org/showtest.asp?testid=6766\\&format=long -OR-\n* Newly diagnosed Minnesota standard risk aGVHD Ann Arbor 3 biomarkers tested by Viracor. For ordering information, see: https://www.viracor-eurofins.com/test-menu/403572p-agvhd-symptomatic- onset-algorithm/\n\n  * Renal: Serum creatinine \u22642.5x upper limit of normal (ULN)\n  * Cardiac: Left ventricular ejection fraction (LVEF) \u2265 35%\n  * Voluntary written consent (adult or parent/guardian with minor assent for 12 through 17-year-olds).\n\nExclusion Criteria:\n\n* Progressive malignancy\n* Uncontrolled bacterial, fungal, parasitic, or viral infection at initiation of protocol treatment\n* Unwilling or unable to stop supplemental sex hormone therapy (estrogen, progesterone, and/or testosterone preparations)\n* Unwilling or unable to stop GnRH antagonists, aromatase inhibitors, or anti-androgens\n* History of a hormone responsive malignancy\n* Current thromboembolic disease requiring full-dose anticoagulation - patients receiving pharmacologic prophylaxis for thromboembolic disease will be eligible\n* Active or recent (within prior 3 months) thrombus, irrespective of anticoagulation status\n* Pregnancy\n* Women or men of childbearing potential unwilling to take adequate precautions to avoid unintended pregnancy from the start of protocol treatment through 30 days after the last treatment",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "12 Years",
            "stdAges": [
                "CHILD",
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Cancer Center Clinical Trials Office",
                    "role": "CONTACT",
                    "phone": "612 624 2620",
                    "email": "ccinfo@umn.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Sherman Holtan, MD",
                    "affiliation": "Masonic Cancer Center, University of Minnesota",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Masonic Cancer Center at University of Minnesota",
                    "status": "RECRUITING",
                    "city": "Minneapolis",
                    "state": "Minnesota",
                    "zip": "55455",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Cancer Center Clinical Trials Office",
                            "role": "CONTACT",
                            "phone": "612-624-2620",
                            "email": "ccinfo@umn.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.97997,
                        "lon": -93.26384
                    }
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006086",
                    "term": "Graft vs Host Disease"
                }
            ],
            "ancestors": [
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9189",
                    "name": "Graft vs Host Disease",
                    "asFound": "Graft Versus Host Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "asFound": "Acute Graft Versus Host Disease",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2832",
                    "name": "Homologous Wasting Disease",
                    "asFound": "Graft Versus Host Disease",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011241",
                    "term": "Prednisone"
                },
                {
                    "id": "D000008775",
                    "term": "Methylprednisolone"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                },
                {
                    "id": "D000005938",
                    "term": "Glucocorticoids"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000000932",
                    "term": "Antiemetics"
                },
                {
                    "id": "D000001337",
                    "term": "Autonomic Agents"
                },
                {
                    "id": "D000018373",
                    "term": "Peripheral Nervous System Agents"
                },
                {
                    "id": "D000005765",
                    "term": "Gastrointestinal Agents"
                },
                {
                    "id": "D000018696",
                    "term": "Neuroprotective Agents"
                },
                {
                    "id": "D000020011",
                    "term": "Protective Agents"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14121",
                    "name": "Prednisone",
                    "asFound": "Prospective",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11749",
                    "name": "Methylprednisolone",
                    "asFound": "Fixed",
                    "relevance": "HIGH"
                },
                {
                    "id": "M1833",
                    "name": "Methylprednisolone Acetate",
                    "relevance": "LOW"
                },
                {
                    "id": "M11750",
                    "name": "Methylprednisolone Hemisuccinate",
                    "relevance": "LOW"
                },
                {
                    "id": "M14120",
                    "name": "Prednisolone",
                    "relevance": "LOW"
                },
                {
                    "id": "M229449",
                    "name": "Prednisolone acetate",
                    "relevance": "LOW"
                },
                {
                    "id": "M211887",
                    "name": "Prednisolone hemisuccinate",
                    "relevance": "LOW"
                },
                {
                    "id": "M248881",
                    "name": "Prednisolone phosphate",
                    "relevance": "LOW"
                },
                {
                    "id": "M9168",
                    "name": "Chorionic Gonadotropin",
                    "relevance": "LOW"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9047",
                    "name": "Glucocorticoids",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M4251",
                    "name": "Antiemetics",
                    "relevance": "LOW"
                },
                {
                    "id": "M8881",
                    "name": "Gastrointestinal Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M20773",
                    "name": "Neuroprotective Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M21869",
                    "name": "Protective Agents",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "AnEm",
                    "name": "Antiemetics"
                },
                {
                    "abbrev": "NeuroAg",
                    "name": "Neuroprotective Agents"
                },
                {
                    "abbrev": "Gast",
                    "name": "Gastrointestinal Agents"
                },
                {
                    "abbrev": "Repr",
                    "name": "Reproductive Control Agents"
                }
            ]
        }
    },
    "hasResults": false
}